A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT01381900
First received: June 23, 2011
Last updated: April 23, 2014
Last verified: April 2014
Results First Received: November 21, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver);   Primary Purpose: Treatment
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo
Drug: Canagliflozin 100mg
Drug: Canagliflozin 300mg
Drug: Metformin
Drug: Sulphonylurea

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This study evaluated the efficacy and safety of canagliflozin in Asian participants with type 2 diabetes mellitus who had inadequate glycemic control on a maximally effective or tolerated dose of metformin alone or metformin plus sulphonylurea (SU). It was conducted between 30 June 2011 and 21 December 2012 and recruited patients from 36 sites.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The study had two background treatment strata: 331 participants in the metformin alone stratum and 347 in the metformin plus SU. In total, 678 participants were randomly allocated to the 3 treatment arms, 676 received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set and the safety analysis set.

Reporting Groups
  Description
Placebo Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
Canagliflozin 100 mg Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
Canagliflozin 300 mg Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.

Participant Flow:   Overall Study
    Placebo     Canagliflozin 100 mg     Canagliflozin 300 mg  
STARTED     226     223     227  
COMPLETED     217     214     215  
NOT COMPLETED     9     9     12  
Subject meets glycemic withdrawal crit.                 2                 0                 0  
Adverse Event                 4                 6                 7  
Noncompliance with study drug                 0                 0                 1  
Physician Decision                 0                 1                 1  
Protocol Violation                 0                 1                 1  
Withdrawal by Subject                 0                 0                 1  
Early withdraw                 3                 1                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
Canagliflozin 100 mg Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
Canagliflozin 300 mg Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
Total Total of all reporting groups

Baseline Measures
    Placebo     Canagliflozin 100 mg     Canagliflozin 300 mg     Total  
Number of Participants  
[units: participants]
  226     223     227     676  
Age  
[units: participants]
       
<=18 years     0     0     0     0  
Between 18 and 65 years     184     187     186     557  
>=65 years     42     36     41     119  
Age  
[units: years]
Mean ± Standard Deviation
  55.8  ± 9.35     56.5  ± 8.25     56.4  ± 9.21     56.3  ± 8.94  
Gender  
[units: participants]
       
Female     101     99     114     314  
Male     125     124     113     362  
Region Enroll  
[units: participants]
       
China     213     210     213     636  
Malaysia     3     5     4     12  
Vietnam     10     8     10     28  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18   [ Time Frame: Day 1 (Baseline) and Week 18 ]

2.  Secondary:   Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18   [ Time Frame: Day 1 (Baseline) and Week 18 ]

3.  Secondary:   Percent Change in Body Weight From Baseline to Week 18   [ Time Frame: Day 1 (Baseline) and Week 18 ]
  Hide Outcome Measure 3

Measure Type Secondary
Measure Title Percent Change in Body Weight From Baseline to Week 18
Measure Description The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
Time Frame Day 1 (Baseline) and Week 18  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Analysis used overall mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 18 values. Table includes only participants with both baseline and post baseline values.

Reporting Groups
  Description
Placebo Each participant received matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
Canagliflozin 100 mg Each participant received 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
Canagliflozin 300 mg Each participant received 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.

Measured Values
    Placebo     Canagliflozin 100 mg     Canagliflozin 300 mg  
Number of Participants Analyzed  
[units: participants]
  226     223     227  
Percent Change in Body Weight From Baseline to Week 18  
[units: Pecent┬áchange]
Least Squares Mean ± Standard Error
  -0.8  ± 0.4     -2.9  ± 0.4     -3.1  ± 0.4  


Statistical Analysis 1 for Percent Change in Body Weight From Baseline to Week 18
Groups [1] Placebo vs. Canagliflozin 100 mg
Method [2] ANCOVA
P Value [3] <0.001
Least-Squares Mean Difference [4] -2.2
Standard Error of the mean ± 0.3
95% Confidence Interval ( -2.7 to -1.6 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  No text entered.
[4] Other relevant estimation information:
  No text entered.

Statistical Analysis 2 for Percent Change in Body Weight From Baseline to Week 18
Groups [1] Placebo vs. Canagliflozin 300 mg
Method [2] ANCOVA
P Value [3] <0.001
Least-Squares Mean Difference [4] -2.3
Standard Error of the mean ± 0.3
95% Confidence Interval ( -2.9 to -1.8 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  No text entered.
[4] Other relevant estimation information:
  No text entered.



4.  Secondary:   Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <7% at Week 18   [ Time Frame: Day 1 (Baseline) and Week 18 ]

5.  Secondary:   Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18   [ Time Frame: Day 1 (Baseline) and Week 18 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information